Preoperative prediction of pathological grade in pancreatic ductal adenocarcinoma based on

18F-FDG PET/CT Machine learning Pancreatic cancer Radiomics XGBoost

Journal

EJNMMI research
ISSN: 2191-219X
Titre abrégé: EJNMMI Res
Pays: Germany
ID NLM: 101560946

Informations de publication

Date de publication:
25 Feb 2021
Historique:
received: 02 11 2020
accepted: 10 02 2021
entrez: 25 2 2021
pubmed: 26 2 2021
medline: 26 2 2021
Statut: epublish

Résumé

To develop and validate a machine learning model based on radiomic features derived from A total of 149 patients (83 men, 66 women, mean age 61 years old) with pathologically proven PDAC and a preoperative The prediction model based on a twelve-feature-combined radiomics signature could stratify PDAC patients into grade 1 and grade 2/3 groups with AUC of 0.994 in the training set and 0.921 in the validation set. The model developed is capable of predicting pathological differentiation grade of PDAC based on preoperative

Identifiants

pubmed: 33630176
doi: 10.1186/s13550-021-00760-3
pii: 10.1186/s13550-021-00760-3
pmc: PMC7907291
doi:

Types de publication

Journal Article

Langues

eng

Pagination

19

Subventions

Organisme : National Natural Science Foundation of China
ID : 82071967
Organisme : CAMS Initiative for Innovative Medicine
ID : CAMS-2018-I2M-3-001
Organisme : Tsinghua University-Peking Union Medical College Hospital Initiative Scientific Research Program
ID : 52300300519

Références

Eur J Nucl Med Mol Imaging. 2018 Sep;45(10):1649-1660
pubmed: 29623375
Abdom Radiol (NY). 2018 Feb;43(2):415-434
pubmed: 29143875
Cancer Manag Res. 2019 Oct 30;11:9253-9264
pubmed: 31802945
Acad Radiol. 2020 Aug;27(8):e183-e192
pubmed: 31761665
HPB (Oxford). 2019 Feb;21(2):212-218
pubmed: 30097414
Nucl Med Mol Imaging. 2018 Jun;52(3):170-189
pubmed: 29942396
Clin Transl Oncol. 2017 Jun;19(6):667-681
pubmed: 27995549
Cancer Res. 2017 Nov 1;77(21):e104-e107
pubmed: 29092951
Clin Lung Cancer. 2016 Sep;17(5):441-448.e6
pubmed: 27017476
Lancet. 2011 Aug 13;378(9791):607-20
pubmed: 21620466
J Nucl Med. 2017 Mar;58(3):387-392
pubmed: 27754906
Eur J Radiol. 2017 May;90:152-158
pubmed: 28583627
World J Gastroenterol. 2013 Aug 7;19(29):4808-17
pubmed: 23922481
Radiology. 2016 Feb;278(2):563-77
pubmed: 26579733
World J Gastroenterol. 2014 Aug 28;20(32):11142-59
pubmed: 25170201
Med Phys. 2019 Oct;46(10):4520-4530
pubmed: 31348535
Dig Liver Dis. 2016 Mar;48(3):223-30
pubmed: 26769569
World J Gastroenterol. 2014 Jun 28;20(24):7808-18
pubmed: 24976719
N Am J Med Sci. 2016 Jan;8(1):1-11
pubmed: 27011940
Surgery. 2014 May;155(5):887-92
pubmed: 24661765
Eur J Cancer. 2012 Mar;48(4):441-6
pubmed: 22257792
Front Oncol. 2016 Mar 30;6:71
pubmed: 27064691
Radiographics. 2017 Sep-Oct;37(5):1483-1503
pubmed: 28898189
Eur Radiol Exp. 2019 Oct 17;3(1):41
pubmed: 31624935
J Clin Epidemiol. 2015 Mar;68(3):279-89
pubmed: 25179855
J Nucl Med. 2014 Jun;55(6):898-904
pubmed: 24711649
Surgery. 2016 Jun;159(6):1520-1527
pubmed: 26847803
Mol Imaging Biol. 2019 Dec;21(6):1200-1209
pubmed: 30847822
Nat Commun. 2014 Jun 03;5:4006
pubmed: 24892406
Clin Cancer Res. 2019 Jan 15;25(2):584-594
pubmed: 30397175
Acta Oncol. 2017 Nov;56(11):1531-1536
pubmed: 28820287
Sci Rep. 2018 May 8;8(1):7226
pubmed: 29740111
Eur J Nucl Med Mol Imaging. 2021 Feb;48(2):350-360
pubmed: 32776232
JAMA Oncol. 2016 Mar;2(3):380-1
pubmed: 26658827
World J Gastroenterol. 2014 Aug 21;20(31):10802-12
pubmed: 25152583
Clin Nucl Med. 2019 Dec;44(12):956-960
pubmed: 31689276
Cancer Med. 2020 Jun;9(12):4059-4068
pubmed: 32281301
Eur J Nucl Med Mol Imaging. 2018 Feb;45(2):207-217
pubmed: 28944403
Nat Rev Clin Oncol. 2017 Dec;14(12):749-762
pubmed: 28975929

Auteurs

Haiqun Xing (H)

Department of Nuclear Medicine, Peking Union Medical College Hospital, Dongcheng District, Chinese Academy of Medical Science, Peking Union Medical College, No.1 Shuaifuyuan, Beijing, 100730, China.
Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Beijing, 100730, China.

Zhixin Hao (Z)

Department of Nuclear Medicine, Peking Union Medical College Hospital, Dongcheng District, Chinese Academy of Medical Science, Peking Union Medical College, No.1 Shuaifuyuan, Beijing, 100730, China.
Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Beijing, 100730, China.

Wenjia Zhu (W)

Department of Nuclear Medicine, Peking Union Medical College Hospital, Dongcheng District, Chinese Academy of Medical Science, Peking Union Medical College, No.1 Shuaifuyuan, Beijing, 100730, China.
Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Beijing, 100730, China.

Dehui Sun (D)

Sinounion Healthcare Inc., Building 3-B, Zhongguancun Dong Sheng International Pioneer Park, Beijing, 100192, China.

Jie Ding (J)

Department of Nuclear Medicine, Peking Union Medical College Hospital, Dongcheng District, Chinese Academy of Medical Science, Peking Union Medical College, No.1 Shuaifuyuan, Beijing, 100730, China.
Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Beijing, 100730, China.

Hui Zhang (H)

Department of Biomedical Engineering, School of Medicine, Tsinghua University, Beijing, 100084, China.

Yu Liu (Y)

Department of Nuclear Medicine, Peking Union Medical College Hospital, Dongcheng District, Chinese Academy of Medical Science, Peking Union Medical College, No.1 Shuaifuyuan, Beijing, 100730, China.
Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Beijing, 100730, China.

Li Huo (L)

Department of Nuclear Medicine, Peking Union Medical College Hospital, Dongcheng District, Chinese Academy of Medical Science, Peking Union Medical College, No.1 Shuaifuyuan, Beijing, 100730, China. huoli@pumch.cn.
Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Beijing, 100730, China. huoli@pumch.cn.

Classifications MeSH